AbbVie Stock Bank It or Tank It

############################# Video Source: www.youtube.com/watch?v=JbyaWTavUfA

Pharma giant Abbvie's (NYSE: ABBV) flagship medication Humira is a huge seller in the U.S. and abroad. But as more companies develop their own generic versions, the drug maker is facing tighter competition. With its recent acquisition of Botox-maker Allergan, Abbvie is looking to set new sales records in 2020. I’ll review Abbvie’s balance sheet and fundamentals to let you know whether you should expect the stock to surge — or fall even further this year. • If you're interested in checking out my brand-new, free Options 101 course, you can learn more right here: https://research.banyanhill.com/1468491 • About Me: I'm a CMT, editor of popular options-trading services Pure Income, Quick Hit Profits, and Automatic Profits Alert, and a weekly contributor to Banyan Hill's Winning Investor Daily. You may have also read some of my work on Investopedia. I've dedicated this channel to sharing the best opportunities to generate steady monthly income in an easy-to-digest format. My trading philosophy is deeply rooted in historical patterns and reliable technical indicators. So if you want to learn to trade using my proven strategies, be sure to subscribe! • Follow me on Social Media! • Twitter: / chadshoopguru • Facebook: / chadshoopguru • Instagram: / chadshoopguru • Check out my blog and recommended investment resources at https://chadshoopguru.com • Like the info in this video? Comment below and tell me why! • I love reading requests for new video topics, so feel free to share what you’d like to hear in future videos!

#############################

New on site